The “Restart Your Business with BV” Suite of Solutions Is Enhanced With a Digital Ecosystem
13.5.2020 18:52:00 EEST | Business Wire | Press release
Bureau Veritas , a world leader in testing, inspection and certification (TIC), is offering a digital platform to support companies and public authorities in their health protocols and their commitment to transparency.
The platform includes a set of applications that enhances the "Restart Your Business with BV" suite of solutions. Launched by Bureau Veritas at the end of April, it meets the needs of companies getting ready to restart their business activities in the right sanitary conditions.
The platform includes operational assistance tools for companies who want to reassure stakeholders on their compliance with regulations and recommended protective measures and benefit from a label with online information for end-users and consumers.
Through the "Restart Your Business with BV" initiative, Bureau Veritas is leveraging its expertise in certification processes and management of health, safety and hygiene risks to support economic recovery.
Bureau Veritas' digital ecosystem meets two requirements of companies and public authorities:
- Traceability: it provides dashboards that house all the information and KPIs collected in the field as well as an overall view of compliance, at a global level, and at specific location or site level.
- Transparency: it allows members of the general public to check that a facility has a valid label and to locate other sites with valid labels on a map. All information provided can be reused by customers on their own websites and applications, and by third parties according to the open data principle.
In a context where time is of the essence for business resumption, Bureau Veritas also offers companies the ability to register online in order to get their label application process started quickly.
For more information on “Restart Your Business with BV” please contact: restartwithbv@bureauveritas.com
About Bureau Veritas
Bureau Veritas is a world-leading provider in testing, inspection and certification. Created in 1828, the Group has more than 78,000 employees located in more than 1,500 offices and laboratories around the globe. Bureau Veritas helps its clients to improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the Next 20 index.
Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on Twitter (@bureauveritas) and LinkedIn.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005568/en/
Contact information
ANALYST/ INVESTOR CONTACTS
Laurent Brunelle
+33 (0)1 55 24 76 09
laurent.brunelle@bureauveritas.com
Florent Chaix
+33 (0)1 55 24 77 80
florent.chaix@bureauveritas.com
MEDIA CONTACTS
Véronique Gielec
+33 (0)1 55 24 76 01
veronique.gielec@bureauveritas.com
DGM Conseil
+33 (0)1 40 70 11 89
thomasdeclimens@dgm-conseil.fr
quentin.hua@dgm-conseil.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur ® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 14:00:00 EEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
Infobip Launches PitchMate — An AI Fan Companion for Global Football2.7.2026 13:00:00 EEST | Press release
Global AI-first cloud communications platform Infobip launched PitchMate, a new AI-powered conversational agent that brings football fans closer to the action of the world’s biggest football tournament. Purpose-built for the global football audience, PitchMate joins the TGR Haas F1 Team RaceMate — Infobip’s AI fan engagement solution for the TGR Haas F1 Team — in demonstrating how conversational AI is transforming fan engagement across sports worldwide. RaceMate, launched last April for this year’s motorsport season, is an AI agent on WhatsApp and Apple Messages for Business that puts TGR Haas F1 Team fans at the center of the action. It delivers real-time race data, personalized content, team radio highlights, trivia, and native multilingual support, turning passive viewers into active participants through natural, human-like conversations across every race weekend. Since its launch, RaceMate has reached users in more than 60 countries, achieving more than 40,000 messages exchanged wi
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies2.7.2026 12:00:00 EEST | Press release
Besins Healthcare, a global pharmaceutical company specializing in hormonal health, today announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognized expertise in long-acting drug delivery technologies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701779777/en/ Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies This acquisition brings together two highly compatible areas. Besins Healthcare brings deep expertise in hormone therapies for women’s and men’s health, including treatments such as Estrogel®/Oestrogel® (estradiol)2 and Utrogestan®3 (micronized progesterone) for women, and Androgel®/Testogel®4 (testosterone) for men. UniD contributes advanced capabilities in technologies that can enable more differentiated, less frequentl
ROYC Selected by Slättö as Structuring and Platform Solution for Luxembourg Feeder Fund2.7.2026 11:45:00 EEST | Press release
ROYC, a leading global structuring and platform provider, today announced that Slättö, a Nordic private markets real estate firm, has selected ROYC to establish and manage a Luxembourg-domiciled feeder fund designed to efficiently aggregate individual subscriptions from professional investors. The Luxembourg-domiciled vehicle will be fully structured and administered on ROYC’s proprietary platform, delivering investors a seamless digital experience with real-time portfolio access, automated reporting, and efficient global distribution. ROYC streamlines onboarding and governance, standardizes legal documentation, and broadens access to capital. “Private markets are undergoing a structural shift as global banks and wealth platforms increasingly seek efficient access to high-quality private equity strategies. By combining our deep structuring expertise with ROYC’s digital operating infrastructure, we enable leading managers like Slättö to launch investor-ready vehicles rapidly while deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom